Toll-interacting protein (TOLLIP)

Toll-interacting protein (TOLLIP) is an intracellular adaptor protein critical for regulating innate immune receptor signaling, especially in the pathways downstream of Toll-like receptors (TLRs) and the interleukin-1 receptor. It functions primarily as a negative regulator by associating with TLR2, TLR4, and IL-1 receptor complexes, inhibiting the interleukin-1 receptor–associated kinase (IRAK) and thus dampening NF-κB activation and cytokine production during strong inflammatory stimuli[1][2][3][4][6]. TOLLIP also mediates endocytic trafficking and lysosomal degradation of receptor complexes and, as a ubiquitin-binding protein, participates in autophagy and protein quality control. Alterations in TOLLIP function are implicated in inflammatory, infectious, fibrotic, and cardiovascular diseases. Multiple TOLLIP gene variants have been associated with susceptibility to diseases where immune modulation and receptor trafficking play a role[1][2][3][6]. **Note:** - There are currently no approved drugs targeting TOLLIP directly (no pharmacological modulators listed in the biomedical databases as of now). - TOLLIP is generally considered a valid immune modulator and research target, but not a classic drug target receptor or enzyme.

Other names

Toll-interacting proteinIL-1RAcPIPtoll-interacting adaptor proteinTOLLIP

Negative regulation of NF-κB activation and cytokine production (by inhibiting IRAK activity in TLR and IL-1 receptor pathways); Endosomal sorting and degradation of receptor complexes via ubiquitin-dependent mechanisms